Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Selective Modulation of Gamma-Secretase May Reverse Alzheimer's Disease

By BiotechDaily International staff writers
Posted on 22 Aug 2013
Print article
Image: Enzymes act on the APP (Amyloid precursor protein) and cut it into fragments of protein, one of which is called beta-amyloid, which is crucial in the formation of senile plaques in Alzheimer's disease (Photo courtesy of Wikimedia Commons).
Image: Enzymes act on the APP (Amyloid precursor protein) and cut it into fragments of protein, one of which is called beta-amyloid, which is crucial in the formation of senile plaques in Alzheimer's disease (Photo courtesy of Wikimedia Commons).
A new generation of drugs for treatment of Alzheimer's disease (AD) will prevent formation of amyloid-beta peptide-42 (A-beta42), the accumulation of which is considered by many researchers to be the cause of the disease.

In most forms of AD, abnormally large quantities of the long amyloid peptide-42 are formed due to the inappropriate action of the cleavage enzyme gamma-secretase. Gamma-secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma-secretase is amyloid precursor protein (APP), a large integral membrane protein that, when cleaved by both gamma-and beta-secretase, produces a short 39–42 amino acid peptide called amyloid-beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma-secretase is also critical in the related processing of the Notch protein.

Investigators at the Ecole Polytechnique Fédérale de Lausanne (Switzerland) studied a particularly aggressive early-onset type of familial Alzheimer’s disease that appears as early as thirty years of age and leaves patients with a life expectancy of only a few years.

They reported in the August 2, 2013, online edition of the journal Nature Communications that this syndrome was caused by mutations in the transmembrane domain of APP that affected both gamma- and epsilon-cleavage sites, by raising the A-beta42/40 ratio. The longer A-beta42 peptide is the form that aggregates into toxic amyloid plaques.

New drugs now under development change the location where gamma secretase cleaves the APP protein, thus producing amyloid peptide 38 instead of 42, which is shorter and does not aggregate into plaques.

"Scientists have been trying to target gamma secretase to treat Alzheimer's for over a decade," said senior author Dr. Patrick Fraering, professor of neurosciences at the Ecole Polytechnique Fédérale de Lausanne. "Our work suggests that next-generation molecules, by modulating rather than inhibiting the enzyme, could have few, if any, side-effects. It is tremendously encouraging."

Related Links:

Ecole Polytechnique Fédérale de Lausanne



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.